Lupin Launches Generic Dapagliflozin-Metformin XR Tablets in US as Xigduo XR Alternative

Key Takeaways

• Lupin received FDA approval for generic dapagliflozin-metformin XR tablets in four strengths (5mg/500mg, 5mg/1000mg, 10mg/500mg, 10mg/1000mg)
• The generic version is bioequivalent to AstraZeneca’s Xigduo XR, potentially offering more affordable diabetes treatment options
• Launch provides US patients with expanded access to combination SGLT2 inhibitor and metformin therapy for type 2 diabetes management

---

Mumbai-based pharmaceutical company Lupin Limited announced the US launch of generic dapagliflozin and metformin hydrochloride extended-release tablets following FDA approval of its Abbreviated New Drug Application (ANDA).

The FDA approved Lupin’s generic formulation as bioequivalent to AstraZeneca’s branded Xigduo XR, clearing the way for market entry across four dosage strengths: 5mg/500mg, 5mg/1000mg, 10mg/500mg, and 10mg/1000mg.

Market Impact and Patient Access

The generic launch represents a significant development in the type 2 diabetes treatment landscape, where combination therapies have become increasingly important for glycemic control. Dapagliflozin, an SGLT2 inhibitor, works alongside metformin to provide dual-mechanism glucose management through different pathways.

Lupin’s entry into this market segment aligns with the company’s strategic focus on complex generics and diabetes care. The extended-release formulation offers patients convenient once-daily dosing while maintaining therapeutic efficacy comparable to the reference product.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Regulatory Milestone

The FDA’s bioequivalence determination confirms that Lupin’s generic version delivers the same clinical benefits as Xigduo XR. This regulatory milestone follows comprehensive bioavailability studies demonstrating equivalent absorption rates and therapeutic outcomes.

Generic competition in the diabetes medication space typically leads to increased affordability and broader patient access, particularly important given the chronic nature of type 2 diabetes management requiring long-term medication adherence.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Company Portfolio Expansion

For Lupin, this launch strengthens its US diabetes portfolio and demonstrates continued capability in developing complex combination products. The company has established a significant presence in the US generic market, with diabetes medications representing a key therapeutic focus area.

The timing of this launch positions Lupin to capture market share in the growing SGLT2 inhibitor combination therapy segment, where demand continues expanding due to proven cardiovascular and renal benefits beyond glucose control.

---

Frequently Asked Questions

What does this mean for patients currently taking Xigduo XR?

Patients now have access to a bioequivalent generic alternative that provides the same therapeutic benefits as Xigduo XR, potentially at a lower cost. Patients should consult their healthcare providers before switching medications.

When will Lupin’s generic dapagliflozin-metformin be available in pharmacies?

Lupin has announced the launch following FDA approval, meaning the medication should be available in US pharmacies now. Availability may vary by location and pharmacy.

How does this generic compare to the brand-name Xigduo XR?

The FDA has determined Lupin’s generic version is bioequivalent to Xigduo XR, meaning it contains the same active ingredients in the same strengths and provides equivalent therapeutic effects and safety profile.

Related coverage

• Vertex launches Journavx after FDA approval for acute pain